First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.

Autor: Schreiber AR; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Kagihara JA; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.; Division of Medical Oncology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA., Corr BR; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Davis SL; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Lieu C; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Kim SS; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Jimeno A; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Camidge DR; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Williams J; OnKure, Inc., Boulder, CO 80301, USA., Heim AM; OnKure, Inc., Boulder, CO 80301, USA., Martin A; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., DeMattei JA; OnKure, Inc., Boulder, CO 80301, USA., Holay N; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA., Triplett TA; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.; Department of Immunotherapeutics and Biotechnology, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA., Eckhardt SG; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77054, USA., Litwiler K; OnKure, Inc., Boulder, CO 80301, USA., Winkler J; OnKure, Inc., Boulder, CO 80301, USA., Piscopio AD; OnKure, Inc., Boulder, CO 80301, USA., Diamond JR; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

Publikováno v: Cancers [Cancers (Basel)] 2023 Dec 23; Vol. 16 (1). Date of Electronic Publication: 2023 Dec 23.

990O Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors

Autor: Perets, R., Stemmer, S.M., Geva, R., Golan, T., Fakih, M., Cohen, J.E., Lieu, C., Jin, Z., Lorusso, P., Friedman, I., Hakim, M., Haves Ziv, D., Hashmueli, S., Mandel, I., Ben Moshe, T., Crawford, N., Abbadessa, G., Perez, R., Wu, M., Borad, M.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S675-S675

Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer.

Autor: Stuart CM; Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado School of Medicine, Aurora, CO; Surgical Outcomes and Applied Research Program, Department of Surgery, University of Colorado School of Medicine, Aurora, CO. Electronic address: Christina.Stuart@cuanschutz.edu., Kirsch MJ; Department of Surgery, Division of Surgical Oncology, University of Colorado School of Medicine, Aurora, CO., Zhuang Y; Surgical Outcomes and Applied Research Program, Department of Surgery, University of Colorado School of Medicine, Aurora, CO., Meguid CL; Department of Surgery, Division of Surgical Oncology, University of Colorado School of Medicine, Aurora, CO., Sugawara T; Department of Surgery, Division of Surgical Oncology, University of Colorado School of Medicine, Aurora, CO; Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Japan., Colborn KL; Surgical Outcomes and Applied Research Program, Department of Surgery, University of Colorado School of Medicine, Aurora, CO., Messersmith W; Department of Medicine, University of Colorado School of Medicine, Aurora, CO., Lieu C; Department of Medicine, University of Colorado School of Medicine, Aurora, CO., Gleisner AL; Department of Surgery, Division of Surgical Oncology, University of Colorado School of Medicine, Aurora, CO., Del Chiaro M; Department of Surgery, Division of Surgical Oncology, University of Colorado School of Medicine, Aurora, CO., Schulick RD; Department of Surgery, Division of Surgical Oncology, University of Colorado School of Medicine, Aurora, CO., Meguid RA; Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado School of Medicine, Aurora, CO; Surgical Outcomes and Applied Research Program, Department of Surgery, University of Colorado School of Medicine, Aurora, CO.

Publikováno v: Surgery [Surgery] 2023 Sep; Vol. 174 (3), pp. 654-659. Date of Electronic Publication: 2023 Jun 28.

Improved Survival After Adjuvant Therapy in Locally Advanced Rectal Cancer Patients With Pathologic Complete Response.

Autor: Lai SH; Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado., Vogel JD; Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado., Vemuru S; Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado., Messersmith W; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado., Lieu C; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado., McCarter MD; Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado., Birnbaum E; Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado., Chapman BC; Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado.

Publikováno v: Diseases of the colon and rectum [Dis Colon Rectum] 2023 Jul 01; Vol. 66 (7), pp. 983-993. Date of Electronic Publication: 2023 Jan 04.

O-12 NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal

Autor: Morris, V., Ciombor, K., Polite, B., Mukherjee, S., Krauss, J., Shields, A., Aranha, O., Hays, J., Kazmi, S., Weinberg, B., Benson, A., Lieu, C., Iqbal, S., Hochster, H., Xiao, L., Eng, C.

Publikováno v: In Annals of Oncology June 2023 34 Supplement 1:S185-S186